Abstract
The potent vasodilatator and messenger molecule nitric oxide (NO) is believed to play a key role in migraine pathogenesis. NO donors such as glyceryl trinitrate (GTN) can cause headache. Infusion of GTN leads to a migraine attack in migraineurs with a latency of 4 to 6 hours. In this review we focus in the role of nitric oxide and the transcription factor nuclear factor-κB (NF-κB) in migraine pathophysiology in humans and animal models. NO is involved in pain transmission, hyperalgesia, chronic pain, inflammation and central sensitization mostly in a cyclic guanosinemonophosphate (cGMP) dependent way. We aim to illustrate how NO is implicated in the induction of a migraine attack in migraineurs and how experimental animal models may help to elucidate the mechanisms of the human GTN response. Because of the role of NO in migraine we try to assess if and how the action of preventative migraine drugs involves the NO pathways. More knowledge about the involvement of NO in the genesis of migraine headache may also provide possible future therapeutic targets for acute migraine therapy.
Keywords: Nitric oxide, NF-κB, migraine, pathophysiology, therapy
CNS & Neurological Disorders - Drug Targets
Title: Nitric Oxide in Migraine
Volume: 6 Issue: 4
Author(s): L. Neeb and U. Reuter
Affiliation:
Keywords: Nitric oxide, NF-κB, migraine, pathophysiology, therapy
Abstract: The potent vasodilatator and messenger molecule nitric oxide (NO) is believed to play a key role in migraine pathogenesis. NO donors such as glyceryl trinitrate (GTN) can cause headache. Infusion of GTN leads to a migraine attack in migraineurs with a latency of 4 to 6 hours. In this review we focus in the role of nitric oxide and the transcription factor nuclear factor-κB (NF-κB) in migraine pathophysiology in humans and animal models. NO is involved in pain transmission, hyperalgesia, chronic pain, inflammation and central sensitization mostly in a cyclic guanosinemonophosphate (cGMP) dependent way. We aim to illustrate how NO is implicated in the induction of a migraine attack in migraineurs and how experimental animal models may help to elucidate the mechanisms of the human GTN response. Because of the role of NO in migraine we try to assess if and how the action of preventative migraine drugs involves the NO pathways. More knowledge about the involvement of NO in the genesis of migraine headache may also provide possible future therapeutic targets for acute migraine therapy.
Export Options
About this article
Cite this article as:
L. Neeb and U. Reuter , Nitric Oxide in Migraine, CNS & Neurological Disorders - Drug Targets 2007; 6 (4) . https://dx.doi.org/10.2174/187152707781387233
DOI https://dx.doi.org/10.2174/187152707781387233 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
microRNAs-based Predictor Factor in Patients with Migraine-ischemic Stroke
MicroRNA The Importance of Precise Documentation of Vaccination by Physicians and Vaccine Providers
Current Drug Safety Increasing Bcl-2 and Neuroglubin Expression in Hypoxic Hippocampal Neurons under Hypoxia Preconditioning and in 3-n-butylphalide Treated Cells under Oxygen Glucose Deprivation/Reoxygenation
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Current Advances in Developing Inhibitors of Bacterial Multidrug Efflux Pumps
Current Medicinal Chemistry Antimicrobial Proteins from Snake Venoms: Direct Bacterial Damage and Activation of Innate Immunity Against Staphylococcus aureus Skin Infection
Current Medicinal Chemistry Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research Oestradiol Signalling in the Hippocampus
Current Neuropharmacology Perspectives and New Aspects of Metalloproteinases’ Inhibitors in the Therapy of CNS Disorders: From Chemistry to Medicine
Current Medicinal Chemistry Micronutrients at the Interface Between Inflammation and Infection Ascorbic Acid and Calciferol. Part 1: General Overview with a Focus on Ascorbic Acid
Inflammation & Allergy - Drug Targets (Discontinued) CT and CT-guided Percutaneous Needle Biopsy in Diagnosis of Primary Pulmonary Cryptococcosis in Immunocompetent Patients
Current Medical Imaging Targeted Vascular Drug Delivery in Cerebral Cancer
Current Pharmaceutical Design The Molecular Genetics of Migraine: Toward the Identification of Responsible Genes
Current Genomics Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design Immune Cell Entry to Central Nervous System - Current Understanding and Prospective Therapeutic Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets Caenorhabditis elegans-based Model Systems for Antifungal Drug Discovery
Current Pharmaceutical Design Treatment of Central Nervous System Involvement Associated with Primary Sjogrens Syndrome
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptor-γ and Its Ligands in the Treatment of Tumors in the Nervous System
Current Stem Cell Research & Therapy New Chemotherapy and Immunotherapy for Tuberculosis
Current Respiratory Medicine Reviews Update on the Development of TB Vaccines
Current Pharmaceutical Biotechnology Advances in the Treatment of Chronic Granulomatous Disease by Gene Therapy
Current Gene Therapy